11-OH-Δ8-THC11-Hydroxy-Δ8-tetrahydrocannabinol
Active metabolite of Δ8-THC, counterpart of 11-OH-THC; formed in much smaller amounts at equal dose.
C₂₁H₃₀O₃
CAS 28646-40-4
- Family
- Metabolite
- Molar mass
- 330.47 g/mol
Updated on
In plain terms
11-OH-Δ8-THC is the molecule the body makes from delta-8-THC, and it too binds the brain's cannabinoid receptor. In a 2025 trial with brownies, its blood level after 20 mg of delta-8 was clearly lower than that of the 11-OH-THC formed from 20 mg of regular THC.
Receptors and activity
Target network
- Binds or modulates
The lower the cited value, the closer the target sits to 11-OH-Δ8-THC: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 11-OH-Δ8-THC.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Binding (function not established)Ki = 52 nM · bovine55 out of 100
Yamamoto I et al. 1998, Biol Pharm Bull (new tab) · [3H]CP-55940 displacement, bovine cortex; competitive inhibition
Pharmacology
11-Hydroxy-Δ8-tetrahydrocannabinol is the 11-hydroxylated metabolite of Δ8-THC, counterpart of 11-OH-THC in the Δ9 series. Foltz et al. identified it in 1970 as the major metabolite of Δ8-THC, in vivo and in liver microsomes, and observed behavioural effects in rats similar to those of THC. It binds the cannabinoid receptor of bovine cortex with a Ki of 52 nM (Yamamoto et al. 1998). Its formation is catalysed mainly by CYP2C9, whose *2, *3, *8 and *9 variants reduce activity 20- to 60-fold (Zhao and Lazarus 2026). In a double-blind crossover trial in 19 adults, blood concentrations of the metabolite after 20 mg of oral Δ8-THC were clearly lower than those of 11-OH-THC after 20 mg of Δ9-THC, and Δ8-THC was less potent at equal dose (Zamarripa et al. 2025). In mice, it is oxidised to 11-oxo-Δ8-THC and then to Δ8-THC-11-oic acid, which binds the receptor poorly.
Key sources.
- Foltz RL, Fentiman AF Jr et al. Metabolite of (−)-trans-Δ8-tetrahydrocannabinol: identification and synthesis. Science 1970;168:844-5 (new tab)PMID 5444059
- Watanabe K, Yamamoto I, Oguri K, Yoshimura H. Metabolic disposition of Δ8-tetrahydrocannabinol and its active metabolites, 11-hydroxy-Δ8-THC and 11-oxo-Δ8-THC, in mice. Drug Metab Dispos 1981;9:261-4 (new tab)PMID 6113937
- Yamamoto I, Kimura T, Kamei A et al. Competitive inhibition of Δ8-tetrahydrocannabinol and its active metabolites for cannabinoid receptor binding. Biol Pharm Bull 1998;21:408-10 (new tab)PMID 9586583
- Järbe TU, McMillan DE. Δ9-THC as a discriminative stimulus in rats and pigeons: generalization to THC metabolites and SP-111. Psychopharmacology (Berl) 1980;71:281-9 (new tab)PMID 6256796
- Zamarripa CA, Spindle TR, Schriefer D et al. A within-subject cross-over trial comparing the acute effects of oral Δ8-THC and Δ9-THC in healthy adults. Drug Alcohol Depend 2025;272:112676 (new tab)PMID 40288059
- Zhao M, Lazarus P. Cytochrome P450-catalyzed hydroxylation of Δ8-tetrahydrocannabinol and implications for pharmacogenetics. Pharmaceutics 2026;18:1149 (new tab)PMID 42797324
- Chan-Hosokawa A, Nguyen L, Lattanzio N, Adams WR. Emergence of delta-8 tetrahydrocannabinol in DUID investigation casework: method development, validation and application. J Anal Toxicol 2022;46:1-9 (new tab)PMID 33754645
- EMCDDA (Ujváry I. et al.), Hexahydrocannabinol (HHC) and related substances, technical report, 2023 (new tab)
- ANSM, decision of 22 May 2024 amending the list of substances classified as narcotics (generic benzo[c]chromene class), supplemented by the decision of 3 June 2024 (new tab)
- ANSM, decision of 6 February 2026 amending the list of substances classified as narcotics and the list of psychotropic substances (tetrahydrocannabinols in annex III) (new tab)
- ANSM, consolidated list of substances classified as narcotics, updated 26/06/2026 (new tab)
History
- Source
- No presence in the cannabis plant is documented. 11-OH-Δ8-THC forms in the body as a phase I metabolite of Δ8-THC; it is also prepared in the laboratory as an analytical standard. The Δ8-THC in market products is itself usually obtained by chemical conversion of CBD (EMCDDA 2023).
Metabolic pathway
No plant pathway: the molecule arises from hydroxylation of the 11-methyl group of Δ8-THC by the microsomal mono-oxygenase system (Watanabe et al. 1981). With recombinant enzymes, CYP2C9 shows an intrinsic clearance more than 6,200 times that of CYP2C19, the only other active CYP tested; the authors name it the main enzyme of this hydroxylation in the intestine, while other CYPs may contribute in the liver. The CYP2C9*2, *3, *8 and *9 variants reduce activity 20- to 60-fold (Zhao and Lazarus 2026).
Legal framework
- European Union
Not listed in the UN conventions; its parent molecule, Δ8-THC, is one of the six positional isomers of THC in Schedule I of the 1971 Convention. No European Union measure of its own was found for the metabolite. Checked 20/10/2026.
- France
Not named in the French narcotics list. It falls under the generic class of benzo[c]chromene derivatives, which allows a hydroxyalkyl function at position 9 (annex IV, ANSM decisions of 22 May and 3 June 2024). Its parent molecule, Δ8-THC, is a tetrahydrocannabinol: the entry "Tetrahydrocannabinols, their esters, ethers, salts as well as the salts of the aforementioned derivatives" was moved from annex IV to annex III by the ANSM decision of 6 February 2026. Checked 20/10/2026.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Metabolite
- Chemistry
C5 side chain · neutral form
- Parent molecule
Active metabolite.
- Verification
Every fact on this entry was checked against its primary sources on 20 October 2026.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Foltz RL, Fentiman AF Jr et al. Metabolite of (−)-trans-Δ8-tetrahydrocannabinol: identification and synthesis. Science 1970;168:844-5 (new tab)PMID 5444059
- Watanabe K, Yamamoto I, Oguri K, Yoshimura H. Metabolic disposition of Δ8-tetrahydrocannabinol and its active metabolites, 11-hydroxy-Δ8-THC and 11-oxo-Δ8-THC, in mice. Drug Metab Dispos 1981;9:261-4 (new tab)PMID 6113937
- Yamamoto I, Kimura T, Kamei A et al. Competitive inhibition of Δ8-tetrahydrocannabinol and its active metabolites for cannabinoid receptor binding. Biol Pharm Bull 1998;21:408-10 (new tab)PMID 9586583
- Järbe TU, McMillan DE. Δ9-THC as a discriminative stimulus in rats and pigeons: generalization to THC metabolites and SP-111. Psychopharmacology (Berl) 1980;71:281-9 (new tab)PMID 6256796
- Zamarripa CA, Spindle TR, Schriefer D et al. A within-subject cross-over trial comparing the acute effects of oral Δ8-THC and Δ9-THC in healthy adults. Drug Alcohol Depend 2025;272:112676 (new tab)PMID 40288059
- Zhao M, Lazarus P. Cytochrome P450-catalyzed hydroxylation of Δ8-tetrahydrocannabinol and implications for pharmacogenetics. Pharmaceutics 2026;18:1149 (new tab)PMID 42797324
- Chan-Hosokawa A, Nguyen L, Lattanzio N, Adams WR. Emergence of delta-8 tetrahydrocannabinol in DUID investigation casework: method development, validation and application. J Anal Toxicol 2022;46:1-9 (new tab)PMID 33754645
- EMCDDA (Ujváry I. et al.), Hexahydrocannabinol (HHC) and related substances, technical report, 2023 (new tab)
- ANSM, decision of 22 May 2024 amending the list of substances classified as narcotics (generic benzo[c]chromene class), supplemented by the decision of 3 June 2024 (new tab)
- ANSM, decision of 6 February 2026 amending the list of substances classified as narcotics and the list of psychotropic substances (tetrahydrocannabinols in annex III) (new tab)
- ANSM, consolidated list of substances classified as narcotics, updated 26/06/2026 (new tab)
Identifiers
Names
- Common name
- 11-Hydroxy-Δ8-tetrahydrocannabinol
- IUPAC name
- (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
- Other names
- 11-OH-Δ8-THC · 11-hydroxy-delta-8-THC · 11-OH-delta8-THC · 7-OH-Δ6-THC
Identifiers
- Formula
- C₂₁H₃₀O₃
- CAS
- 28646-40-4
- PubChem CID
- 185651(new tab)
- InChIKey
- LOUSQMWLMDHRIK-IAGOWNOFSA-N
- SMILES
- CCCCCC1=
CC(= C2[C@@H] 3CC(= CC[C@H] 3C(OC2= C1) (C) C) CO) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.